What You Should Know:
– Oatmeal Health, an innovator in AI-driven cancer screening launches its AI-powered radiology risk stratification platform for lung cancer.
– The solution provides a fully reimbursable second-opinion diagnostic tool covered by Medicare,…
Continue Reading
Existing prognostic models are useful for estimating the prognosis of lung adenocarcinoma patients, but there remains room for improvement. In the current study, we developed a deep learning model based on histopathological images to…
Continue Reading
Simon Rasalingham, chief executive of Behold.ai (Credit: Prix Galien International)
UK-based digital health start-up Behold.ai has entered administration after failing to win any contracts under the government’s AI Diagnostic Fund.
Behold.ai supplies lung cancer AI…
In this interview, Dr. Samir Shah, Chief Medical Officer at Qure.ai, shares why achieving FDA approval is crucial for their AI solutions and for fostering trust in the technology. Dr. Shah discusses how their…
Continue Reading
Claire Peacock, clinical exercise physiologist at UHNM (second left), with members of UHNM’s Heart Support Group (Credit: University Hospitals of North Midlands NHS Trust)
The Heart and Lung Centre at University Hospitals of North…
Continue Reading
Justin Spencer, Chief Financial Officer at Eko Health
What You Should Know:
– Eko Health, a pioneer in AI-powered heart and lung disease detection, announced today the appointment of Justin Spencer as Chief Financial Officer (CFO).
–…
Continue Reading
AI technology is being rolled out at seven NHS trusts within the Greater Manchester Imaging Network to help doctors detect diseases, including lung cancer, quicker.
The solution from global health tech firm Annalise.ai uses AI-powered…
We developed an interpretable model, BOUND (Bayesian netwOrk for large-scale lUng caNcer Digital prescreening), using a comprehensive EHR dataset from the China to improve lung cancer detection rates. BOUND employs Bayesian network uncertainty inference,…
Continue Reading
Lunit collabs with AstraZeneca, secures major deal in France Lunit and AstraZeneca have partnered to develop new AI-powered digital pathology solutions that predict non-small cell lung cancer (NSCLC).
Based on a media release, their collaboration aims…
Advancing precision in lung cancer diagnostics: Lunit’s collaboration with AstraZeneca aims to transform the speed and accuracy of detecting actionable mutations in NSCLC. (Courtesy of Lunit)
What You Should Know:
– Lunit, a provider of AI…
Continue Reading
